US 12,435,152 B2
Humanized BCMA antibody and BCMA-CAR-T cells
Lijun Wu, Berkeley, CA (US); and Vita Golubovskaya, Richmond, CA (US)
Assigned to Caribou Biosciences, Inc., Berkeley, CA (US)
Filed by Caribou Biosciences, Inc., Berkeley, CA (US)
Filed on Sep. 8, 2022, as Appl. No. 17/930,662.
Application 17/930,662 is a continuation of application No. 17/700,160, filed on Mar. 21, 2022, granted, now 11,472,884.
Application 17/700,160 is a continuation of application No. 17/493,386, filed on Oct. 4, 2021, granted, now 11,299,549.
Application 17/493,386 is a continuation of application No. 17/327,232, filed on May 21, 2021, granted, now 11,142,583, issued on Oct. 12, 2021.
Application 17/327,232 is a continuation of application No. 17/148,487, filed on Jan. 13, 2021, granted, now 11,021,542, issued on Jun. 1, 2021.
Application 17/148,487 is a continuation of application No. 17/010,798, filed on Sep. 2, 2020, granted, now 10,927,182, issued on Feb. 23, 2021.
Application 17/010,798 is a continuation of application No. PCT/US2020/013662, filed on Jan. 15, 2020.
Prior Publication US 2024/0182591 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 35/12 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 9/0019 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4215 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); A61K 2035/124 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2239/31 (2023.05); A61K 2239/46 (2023.05); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01)] 18 Claims
 
1. A method of activating immune response against BCMA-expressing tumor cells, the method comprising contacting the tumor cells with engineered immune cells expressing an anti-BCMA chimeric antigen receptor (CAR) having an anti-BCMA single-chain variable fragment (scFv) comprising:
a. a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 5;
b. a transmembrane domain selected from the group consisting of a T cell receptor α chain, a T cell receptor β chain, a CD3 zeta chain, a CD28, a CD38, a CD45, a CD4, a CD5, a CD8, a CD9, a CD16, a CD22, a CD33, a CD37, a CD64, a CD80, a CD86, a CD134, a CD137, an ICOS, a CD154, and a GITR;
c. a co-stimulatory domain selected from the group consisting of a CD28, a 4-1BB, a GITR, an ICOS-1, a CD27, an OX-40, and a DAP10; and
d. a CD3zeta activating domain.